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Name VH gene VH % identity
CDRH3 
length
VDJ                                                             
junction






VJ                          
junction
46472_1 IGHV1-69 93.75 12 AREVNYYSAFDD IGKV3-15 97.85 8 QQYNFWWT
46472_2 IGHV5-10 94.10 20 AAGPTGYDLLTGQYFPYFNY IGLV6-57 95.19 9 QSYHGSDVV
46472_3 IGHV3-30 94.79 14 ARDRSATYYGPFDY IGLV3-19 94.98 12 NSRDNSGNHPVI
46472_4 IGHV3-23 90.97 19 AKDLLSHSGTYSAGSTFDY IGKV1-39 94.98 8 QESYSTNT
46472_5 IGHV4-39 84.19 9 ARLDYSKQT IGKV2-28 96.26 9 MQALQTPLT
46472_6 IGHV4-39 90.72 24 ARRPQYLLLSMTTGRRHHDFVMDV IGKV4-1 97.31 9 QQYYNTPRT
46472_7 IGHV3-64 92.36 11 VKEDTPLVFDS IGKV1-5 93.19 8 QQYDSYST
46472_8 IGHV3-53 84.91 12 ALGRKDYGDYYR IGKV3-20 89.01 11 QQYAPSPPWYI
46472_9 IGHV4-61 95.53 15 ASLPTYGSGRWGIDS IGKV1-12 96.42 9 QQGNSFPLT
46472_10 IGHV3-53 92.63 16 AGFLPVYNNGWSYFDS IGLV1-44 95.09 11 AVWDDSLNGPV
46472_11 IGHV3-23 87.15 13 VKMRTAVVGVTPL IGKV1-6 95.34 9 LQDYNYLFS
46472_12 IGHV1-8 92.01 20 ARDRVERTGNVGFGYYAMDV IGKV1-39 95.34 10 QQTYSSPSYT
46472_13 IGHV3-7 90.97 15 ARVTIVSSFTNRFDP IGKV1-9 90.32 5 QHRVT
46472_14 IGHV3-53 82.81 6 VRGRTY IGKV3-15 92.47 9 QQYNRWLWT
46472_15 IGHV7-4 97.57 23 ARDFDLVVPSATYPPFYYHGMDV IGLV3-19 97.49 13 NSRDSSGDQTFYV
C







































































































































































































































































































































Supplemental Materials 1 
Supplemental Figure Captions 2 
Figure S1. Application of LIBRA-seq to PBMCs from a recovered SARS-CoV donor sample led to 3 
identification of CoV cross-reactive antibodies, related to Figure 1. 4 
(A) Gating scheme for fluorescent-activated cell sorting of recovered SARS-CoV donor. Cells were initially stained 5 
with Ghost Red 780, CD14-APC-Cy7, CD3-FITC, CD19-BV711, and IgG-PE-Cy5 along with a DNA-barcoded 6 
antigen screening library. To detect antigen-positive B cells, cells were washed and treated with a streptavidin-PE 7 
secondary stain. Gates as drawn are based on gates used during the sort, and percentages from the sort are listed. 8 
(B) The categorization of processing of Cell Ranger identified cells after sequencing is shown. 9 
(C) For each combination of CoV antigens, ZM197 Env, and CZA97 Env, the number of B cells with high LIBRA-10 
seq scores (≥1) is displayed as a bar graph. The combination of antigens are displayed by filled circles, showing 11 
which antigens are part of a given combination. Each combination is mutually exclusive. The number of B cells with 12 
high LIBRA-seq scores for each antigen is indicated as a horizontal bar at the bottom left of the panel. 13 
(D) Genetic sequence characteristics of 15 antibody candidates. Percent identity is calculated at the nucleotide level 14 
and CDRH3 and CDRL3 lengths and sequences are noted at the amino acid level.  15 
(E) ELISA binding data against coronavirus S antigens. HIV-specific antibody VRC01 was used as a negative 16 
control and anti-SARS-CoV mouse antibody 240CD was used as a positive control (BEI Resources). ELISAs were 17 
performed in technical duplicates with at least two biological duplicates. Data are represented as mean ± SEM. 18 
(F) ELISA binding data to independent preparations of MERS-CoV S protein. An influenza HA-specific mAb 3602-19 
1707 was used as a negative control along with positive control antibodies 1F8 (expressed and purified 20 
recombinantly) and MERS S1 mAb and MERS S2 mAbs (Sino Biological).  21 
(G) SDS-PAGE gels of MERS-CoV S2P S preparations are shown (preparation 1 – lane 1 & 2, preparation 2 – lane 22 









































































































































































































































































exaPro S- oV RBD
CR3022 46472-12 46472-6 3602-1707
CR3022 86.37 22.87 7.11 2.19
46472-12 51.50 101.30 -2.88 -8.89
SARS-CoV-2
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Figure S2. Cross-reactive CoV antibodies target distinct domains of SARS-CoV-2 S, related to Figure 2. 29 
(A) Cross-reactive antibodies were tested for binding to SARS-CoV-2 S1 domain, SARS-CoV-2 S1 domain D614G, 30 
SARS-CoV-2 S2 domain, and SARS-CoV-2 S (HexaPro). Anti-HIV antibody VRC01 is shown as a negative 31 
control and anti-SARS-CoV antibody 240CD is shown as a positive control. Data are represented as mean ± SEM. 32 
(B) S1-directed antibodies 46472-6 and 46472-12 were tested for binding against SARS-CoV-2 RBD, SARS-CoV 33 
RBD, SARS-CoV-2 NTD, and SARS-CoV-2 S (HexaPro). Anti-HIV antibody VRC01 is shown as a negative 34 
control and anti-SARS-CoV antibody 240CD is shown as positive control. Data are represented as mean ± SEM. 35 
(C) 46472-12 was tested for its ability to block ACE2 binding to SARS-CoV-2 S. Signal shown is anti-Flag tag 36 
detection of an ACE2-Flag tag protein construct. All values are measured by absorbance at 450 nm and denoted as 37 
A450, ACE2 blocking was determined by measuring amount of ACE2 with FLAG tag binding in the presence of each 38 
antibody (concentration 10µg/mL), measured by binding of an anti-FLAG secondary antibody. Experiment was 39 
done in biological replicate and technical triplicates; shown is representative of one replicate with positive control 40 
mAb COV2-2196. Data are represented as mean ± SEM. 41 
(D) A competition ELISA experiment between antibodies 46472-6, 46472-12 and CR3022 was performed to 42 
determine if binding of one antibody to SARS-CoV-2 S affected binding of another. Competitor antibodies were 43 
added at 10 µg/ml, and then detected antibodies were added at 0.1 µg/ml. The percent reduction in binding 44 
compared to binding without a competitor is shown. Influenza HA-specific antibody 3602-1707 was used as a 45 
negative control. ELISAs were performed in technical duplicates with at least two biological duplicates.    46 
(E) 46472-6 and 46472-12 were tested for binding to SARS-CoV-2 S (HexaPro) mutants, N165A and N709A, by 47 
ELISA. Antibody concentration is shown on the x-axis and absorbance at 450 nm is shown on the y-axis. ELISAs 48 
were performed in technical duplicates with at least two biological duplicates. Data are represented as mean ± SEM. 49 
(F)  Mannose competition ELISA binding assays were performed to determine if cross-reactive antibody binding to 50 
SARS-CoV-2 S could be modulated by 1M D-(+)-Mannose. Binding of each antibody with (pink) or without (black) 51 
mannose is shown as a separate plot. Antibody concentration is shown on the x-axis and absorbance at 450 nm is 52 
shown on the y-axis. Antigen-specific antibody CR3022 and HIV-specific negative control antibody VRC01 are also 53 
shown. ELISAs were performed in technical duplicates with at least two biological duplicates. Data are represented 54 
as mean ± SEM. 55 
 56 
Supplemental Figure 3A
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Figure S3. Cross-reactive CoV antibodies are non-neutralizing but demonstrate a variety of Fc effector 57 
functions, related to Figure 3. 58 
(A) Antibodies were tested for neutralization in authentic SARS-CoV and SARS-CoV-2 nanoluciferase-based 59 
assays. Antibody and serum neutralization were measured by relative light units (RLU) via the Nano-Glo Luciferase 60 
System (Promega) compared to virus only control wells. 61 
(B) Antibodies were tested in SARS-CoV-2 RTCA assay. The adhesion of target Vero-furin cells were measured by 62 
electronic sensograms of each antibody and control-treated well and converted into Cell Index values by xCelligence 63 
software. Neutralization was assessed by comparison to virus only and media only controls. 64 
(C) Cross-reactive coronavirus antibodies were tested for ability to mediate antibody-dependent cellular 65 
phagocytosis (ADCP) against SARS-CoV-2 S, compared to antigen-specific control antibody CR3022 and negative 66 
control Palivizumab, an anti-RSV antibody. Phagocytosis score (see Methods) is shown on the y-axis and antibody 67 
concentration is shown on the x-axis. Experiments were performed at least twice, and data is shown as mean +/- the 68 
standard deviation. 69 
(D) 46472-4 and 46472-12 were tested for antibody-dependent cellular phagocytosis activity against SARS-CoV S, 70 
compared to antigen-specific CR3022 antibody and anti-RSV antibody Palivizumab. Phagocytosis score (see 71 
Methods) is shown on the y-axis and antibody concentration is shown on the x-axis. Experiments were performed at 72 
least twice, and data is shown as mean +/- the standard deviation. 73 
(E) Cross-reactive coronavirus antibodies were tested for antibody-dependent cellular trogocytosis activity against 74 
SARS-CoV-2 S displayed on transfected cells, compared to antigen-specific control CR3022 and anti-RSV antibody 75 
Palivizumab. Trogocytosis score (see Methods) is shown on the y-axis and antibody concentration is shown on the 76 
x-axis.  Experiments were performed at least twice, and data is shown as mean +/- the standard deviation. 77 
(F) Cross-reactive coronavirus antibodies were tested for antibody-dependent complement deposition (ADCD) 78 
activity against SARS-CoV-2 S, compared to antigen-specific control CR3022 and anti-RSV antibody Palivizumab. 79 
Complement deposition score (see Methods) is shown on the y-axis and antibody concentration is shown on the x-80 




Animal Survival, Days Post Infection 
Antibody 0 1 2 3 4
46472-12 5/5 5/5 5/5 5/5 4/5
46472-4 5/5 5/5 5/5 4/5 2/5
CR3022 5/5 5/5 5/5 4/5 3/5
DENV-
2D22
5/5 5/5 5/5 5/5 2/5
Animal Survival, Days Post Infection 
Antibody 0 1 2 3 4
46472-12 4/4 4/4 4/4 4/4 4/4
46472-4 5/5 5/5 5/5 5/5 5/5
CR3022 5/5 5/5 5/5 5/5 5/5
DENV-
2D22
5/5 5/5 5/5 5/5 4/5
B
SARS-CoV-2 MA 104 PFUSARS-CoV-2 MA 103 PFU
Figure S4. Antibodies 46472-4 and 46472-12 were tested for prophylaxis in a murine model of SARS-CoV-2 84 
infection, related to Figure 4. 85 
(A) For each antibody treatment group for the experiment utilizing 1x103 PFU of SARS-CoV-2 MA, a table 86 
showing the number of animals to survive per group per day is shown.  87 
(B) For each antibody treatment group for the experiment utilizing 1x104 PFU of SARS-CoV-2 MA, a table 88 
showing the number of animals to survive per group, per day is shown (survival curves shown in Figure 4C). 2/5, 89 
4/5, 3/5, and 2/5 mice survived to day 4 for antibodies 46472-4, 46472-12, CR3022 and isotype control DENV-90 
2D22, respectively.  91 
